Results 151 to 160 of about 41,938 (307)

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

Acta Paediatrica, EarlyView.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz, Raz Somech, Dan Dominissini, Nathan Keller, Efrat Dresner, Michal Paret, Gilad Sherman, Guy Katzenellenbogen, Elina Gelman, Keren Asraf, Ram Doolman, Atar Lev, Amos J. Simon, Helly Vernitsky, Assaf Barg, Hana Golan, Amos Toren, Michal Stein   +17 more
wiley   +1 more source

Checkpoint inhibitors, obinutuzumab plus PET‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘FLUORO’ study

British Journal of Haematology, EarlyView.
Summary Follicular lymphoma (FL) first‐line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment‐naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)
Arina Martynchyk, Geoffrey Chong, Richard Khor, Denise Lee, Sze Ting Lee, Andrew M. Scott, Anneke C. Grobler, Belinda A. Campbell, Thanuja Thachil, Kate Manos, Genevieve Douglas, Alexandra Romano, Jodie B. Palmer, Melinda Burgess, Colm Keane, Eliza A. Hawkes   +15 more
wiley   +1 more source

Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data

British Journal of Haematology, EarlyView.
Summary Functional high‐risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12–24 months of front‐line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front‐line therapies, it is challenging to assign the disease progression to a true FHR phenotype versus less ...
Utkarsh Goel, Catalin Dragomirescu, Saurabh Zanwar, Rafaella Cassano Cassano, Kara I. Cicero, Andrew J. Cowan, Rahul Banerjee, Faiz Anwer, Jack Khouri, Danai Dima   +9 more
wiley   +1 more source

Docetaxel‐Induced Immune Activation Shows Antitumor Synergy With the Tumor‐Targeted CD40 Agonist KK2269

Cancer Science, EarlyView.
CD40 agonists have demonstrated proof‐of‐concept for converting an immunologically cold tumor into a hot tumor in preclinical studies; however, clinically, they have shown limited antitumor efficacy as monotherapy. We tested a tumor‐targeted CD40 agonist, KK2269 (a bispecific antibody that binds to CD40 and EpCAM), in combination with various ...
Yuta Tezuka, Kyoko Kawasaki, Yoshiki Sumitomo, Masato Saito, Akari Yao, Munetoshi Ando   +5 more
wiley   +1 more source

Targeting of peripheral blood T lymphocytes [PDF]

, 1996
Bolhuis, R.L.H. (Reinder), Gratama, J.W. (Jan-Willem), Hoogenboom, L.C.A.   +2 more
core   +1 more source

Orthotopic Esophageal Cancer Xenograft Model in Immunosuppressed Microminipigs for Near‐Infrared Fluorescence Endoscopy

Cancer Science, EarlyView.
We report the first successful orthotopic engraftment of human esophageal squamous cell carcinoma in immunosuppressed microminipigs and demonstrate high‐contrast near‐infrared fluorescence endoscopic detection using EGFR‐targeted cetuximab. This large‐animal model bridges preclinical imaging research and future clinical translation in esophageal cancer.
Takanori Miyake, Yutaka Kawano, Takanori Kashihara, Masaki Takasu, Kentaroh Takagaki, Shota Fujimoto, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Koichi Okamoto, Masahiro Sogabe, Naoki Muguruma, Koichi Tsuneyama, Yasushi Sato, Tetsuji Takayama   +14 more
wiley   +1 more source

Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives

European Journal of Haematology, EarlyView.
ABSTRACT Relapsed and refractory multiple myeloma (RRMM) remains associated with poor outcomes, particularly in patients exposed or refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. Targeting B‐cell maturation antigen (BCMA) has emerged as an effective therapeutic strategy, prompting the development of ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab. [PDF]

Cancer Discov
Mishra A, Meador CB, Kikkeri K, Cunneely Q, Lin M, Carmona-LaSalle TJ, Huang SB, Bell R, Putaturo V, Xia W, Liang JH, Fang J, San Vicente S, Zielinski CE, Digumarthy SR, Hung YP, Yeap BY, Edd JF, Lawrence MS, Sade-Feldman M, Sen DR, Toner M, Maheswaran S, Gainor JF, Haber DA.   +24 more
europepmc   +1 more source

Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs

European Journal of Haematology, EarlyView.
ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Marco Fiorillo, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma. [PDF]

J Immunother Cancer
Corona M, García-Vicente R, Saez-Marin AJ, Ancos-Pintado R, Rodríguez-Garcia A, Arroyo A, Blanco A, Chari A, Martin T, Wolf J, Rey-Bua B, Mateos MV, Kortüm KM, Riedhammer C, Tamariz-Amador LE, Valencia E, Rodríguez-Otero P, San Miguel J, Ibarra G, Oriol A, Cedena MT, López-Muñoz N, Alonso R, Calbacho M, Sanchez-Pina JM, Linares M, Martínez-López J.   +26 more
europepmc   +1 more source